Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Regulatory News (SLN)

  • There is currently no data for SLN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Purchase of ADS and PDMR Shareholding

19 Apr 2021 07:00

RNS Number : 8091V
Silence Therapeutics PLC
19 April 2021
 

Purchase of American Depositary Shares and PDMR Dealings

 

19th April 2021

 

LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that, on 16 April 2021 the following purchases of American Depositary Shares ("ADSs"), each representing three ordinary shares of 5 pence each in the capital of the Company ("Ordinary Shares"), were made by persons discharging managerial responsibilities at a purchase price of $23.09 per ADS: 4,331 ADSs were purchased by Steven Romano, Non-Executive Director of the Company, 4,331 ADSs were purchased by Michael Davidson, MD, Non-Executive Director of the Company, 217 ADSs were purchased by Dave Lemus, Non-Executive Director of the Company, 6,063 ADSs were purchased by Mark Rothera, Chief Executive Officer and Executive Director of the Company and 8,662 ADSs were purchased by Craig Tooman, Chief Financial Officer of the Company.

 

The notifications below, made in accordance with the requirements of the EU Market Abuse Regulation as it forms part of UK law by virtue of the European Union (Withdrawal) Act 2018, provide further detail.

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1.

Details of the person discharging managerial responsibilities (PDMR) / person closely associated

a)

Name

Steven Romano

 

2.

Reason for the notification

a)

Position / status

Non-Executive Director

 

b)

Initial notification / Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Silence Therapeutics plc

 

b)

LEI

213800SSURRJBX85SQ91

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

 

 

 

 

Identification code

American Depositary Shares (ADSs), each of which represents three (3) Ordinary Shares of 5 pence each in the capital of Silence Therapeutics plc

 

 

 

 

ISIN for Silence Therapeutics plc ADSs:

US82686Q1013

b)

Nature of the transaction

 

Purchase of ADSs in Silence Therapeutics plc

 

c)

Price(s) and volume(s)

 

Price

Volume

$23.09

4,331

 

 

d)

Aggregated information

- Aggregated volume

- Price

 

4,331 ADSs

$100,002.79

e)

Date of the transaction

16 April 2021

 

f)

Place of the transaction

Outside a trading venue

 

 

1.

Details of the person discharging managerial responsibilities (PDMR) / person closely associated

a)

Name

Michael Davidson

 

2.

Reason for the notification

a)

Position / status

Non-Executive Director

 

b)

Initial notification / Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Silence Therapeutics plc

 

b)

LEI

213800SSURRJBX85SQ91

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

 

 

Identification code

American Depositary Shares (ADSs), each of which represents three (3) Ordinary Shares of 5 pence each in the capital of Silence Therapeutics plc

 

 

 

ISIN for Silence Therapeutics plc ADSs:

US82686Q1013

b)

Nature of the transaction

Purchase of ADSs in Silence Therapeutics plc

 

c)

Price(s) and volume(s)

 

Price

Volume

$23.09

4,331

 

 

d)

Aggregated information

- Aggregated volume

- Price

 

4,331 ADSs

$100,002.79

e)

Date of the transaction

16 April 2021

 

f)

Place of the transaction

Outside a trading venue

 

 

1.

Details of the person discharging managerial responsibilities (PDMR) / person closely associated

a)

Name

Dave Lemus

 

2.

Reason for the notification

a)

Position / status

Non-Executive Director

 

b)

Initial notification / Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Silence Therapeutics plc

 

b)

LEI

213800SSURRJBX85SQ91

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

 

 

Identification code

American Depositary Shares (ADSs), each of which represents three (3) Ordinary Shares of 5 pence each in the capital of Silence Therapeutics plc

 

 

 

ISIN for Silence Therapeutics plc ADSs:

US82686Q1013

b)

Nature of the transaction

Purchase of ADSs in Silence Therapeutics plc

 

c)

Price(s) and volume(s)

 

Price

Volume

$23.09

217

 

 

d)

Aggregated information

- Aggregated volume

- Price

 

217 ADSs

$5,010.53

e)

Date of the transaction

16 April 2021

 

f)

Place of the transaction

Outside a trading venue

 

 

 

1.

Details of the person discharging managerial responsibilities (PDMR) / person closely associated

a)

Name

Mark Rothera

 

2.

Reason for the notification

a)

Position / status

Chief Executive Officer and Executive Director

 

b)

Initial notification / Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Silence Therapeutics plc

 

b)

LEI

213800SSURRJBX85SQ91

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

 

 

Identification code

American Depositary Shares (ADSs), each of which represents three (3) Ordinary Shares of 5 pence each in the capital of Silence Therapeutics plc

 

 

 

ISIN for Silence Therapeutics plc ADSs:

US82686Q1013

b)

Nature of the transaction

Purchase of ADSs in Silence Therapeutics plc

 

c)

Price(s) and volume(s)

 

Price

Volume

$23.09

6,063

 

 

d)

Aggregated information

- Aggregated volume

- Price

 

6,063 ADSs

$139,994.67

e)

Date of the transaction

16 April 2021

 

 

f)

Place of the transaction

Outside a trading venue

 

 

1.

Details of the person discharging managerial responsibilities (PDMR) / person closely associated

a)

Name

Craig Tooman

 

2.

Reason for the notification

a)

Position / status

Chief Financial Officer

 

b)

Initial notification / Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Silence Therapeutics plc

 

b)

LEI

213800SSURRJBX85SQ91

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

 

 

Identification code

American Depositary Shares (ADSs), each of which represents three (3) Ordinary Shares of 5 pence each in the capital of Silence Therapeutics plc

 

 

 

ISIN for Silence Therapeutics plc ADSs:

US82686Q1013

b)

Nature of the transaction

Purchase of ADSs in Silence Therapeutics plc

 

c)

Price(s) and volume(s)

 

Price

Volume

$23.09

8,662

 

 

d)

Aggregated information

- Aggregated volume

- Price

 

8,662 ADSs

$200,005.58

e)

Date of the transaction

16 April 2021

 

f)

Place of the transaction

Outside a trading venue

 

 

 

 

 

 

Enquiries:

 

Silence Therapeutics plc

 Gem Hopkins, Head of IR & Corporate Communications

Tel: +1 (646) 637-3208

 

Investec Bank plc (Nominated Adviser and Broker)

Daniel Adams/Gary Clarence

 

 

Tel: +44 (0) 20 7597 5970

European PR

Consilium Strategic Communications

Mary-Jane Elliott/Chris Welsh/Angela Gray

silencetherapeutics@consilium-comms.com

 

Tel: +44 (0) 20 3709 5700

 

 

 

About Silence Therapeutics plc

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Silence's proprietary mRNAi GOLD™ platform can be used to create siRNAs that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence's wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address iron loading anemias. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Takeda, among others. For more information, please visit https://www.silence-therapeutics.com/.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHFZGMDGRKGMZZ
Date   Source Headline
28th Apr 20107:00 amPRNSilence (AIM: SLN) to Release Prelim Results on April 29
21st Apr 20107:00 amPRNSilence (AIM:SLN), AstraZeneca Extend RNAi Collaboration
15th Apr 20107:00 amPRNSilence Therapeutics (AIM: SLN) Appoints New CFO
13th Apr 20107:00 amPRNSilence(AIM:SLN) Integrates Assets from Intradigm Merger
30th Mar 20107:02 amPRNResearch Update
19th Mar 20103:27 pmPRNHolding(s) in Company
1st Mar 20107:00 amPRNDirectorate Change
15th Feb 20107:00 amPRNDirector/PDMR Shareholding
12th Feb 20103:28 pmPRNSenior Independent Director
12th Feb 20101:28 pmPRNNotification of Results
28th Jan 20103:00 pmPRNTotal Voting Rights
8th Jan 20101:00 pmPRNHolding(s) in Company
5th Jan 20101:35 pmPRNAcquisition and Issue of Equity
4th Jan 201012:40 pmPRNEGM Statement
17th Dec 200912:05 pmPRNStatement re Posting of Document
16th Dec 20095:03 pmRNSSchedule 1 - Silence Therapeutics plc
16th Dec 200912:00 pmRNSRestoration - Silence Therapeutics plc
16th Dec 200912:00 pmPRNAcquisition
14th Dec 200912:45 pmPRNAGM Statement
20th Nov 20097:00 amPRNNotice of AGM
15th Oct 20097:05 amPRNPatent Update
2nd Oct 20094:55 pmPRNCorrection : Half-yearly Report
30th Sep 20097:00 amPRNHalf-yearly Report
29th Sep 200910:15 amPRNTemporary Suspension
29th Sep 200910:15 amRNSSuspension - Silence Therapeutics plc
17th Sep 20097:00 amPRNNotice of Results
1st Sep 20094:40 pmRNSSecond Price Monitoring Extn
1st Sep 20094:35 pmRNSPrice Monitoring Extension
28th Aug 20094:25 pmPRNHolding(s) in Company
27th Aug 20094:40 pmRNSSecond Price Monitoring Extn
27th Aug 20094:35 pmRNSPrice Monitoring Extension
27th Aug 20097:00 amPRNRe Agreement
26th Aug 200911:30 amPRNHolding(s) in Company
14th Jul 200911:30 amPRNIssue of Equity
1st Jul 20094:40 pmRNSSecond Price Monitoring Extn
1st Jul 20094:35 pmRNSPrice Monitoring Extension
24th Jun 20097:00 amPRNAnnual Financial Report
23rd Jun 20097:00 amPRNResearch Update
19th Jun 20094:35 pmRNSPrice Monitoring Extension
3rd Jun 200912:05 pmPRNStatement re Approval for Clinical Trial
22nd May 20094:40 pmRNSSecond Price Monitoring Extn
22nd May 20094:35 pmRNSPrice Monitoring Extension
12th May 20094:40 pmRNSSecond Price Monitoring Extn
12th May 20094:35 pmRNSPrice Monitoring Extension
11th May 20094:40 pmRNSSecond Price Monitoring Extn
11th May 20094:35 pmRNSPrice Monitoring Extension
7th May 20094:40 pmRNSSecond Price Monitoring Extn
7th May 20094:35 pmRNSPrice Monitoring Extension
5th May 20094:51 pmRNSSecond Price Monitoring Extn
5th May 20094:46 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.